Dr. Matthew Terrence Smith Jr., MD

Dr. Smith practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Smith's NPI, 1205290277, was assigned on April 6, 2016. Dr. Smith graduated from Boston University School Of Medicine in 2016. Dr. Smith holds Texas license V0179.

Dr. Smith's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Smith's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Smith is also affiliated with UnityPoint Health - Iowa Methodist Medical Center. The medical group on file is Physicians Referral Service. Dmand AI also links Dr. Smith to 2 more hospitals, 4 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Smith practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Smith's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Smith is board certified in urology by the American Board of Urology. Dmand AI has Dr. Smith's licenses on file in 4 states: Texas, New York, Ohio and Pennsylvania.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and transurethral procedures among the conditions Dr. Smith treats.

CMS data shows 18 Medicare services from Dr. Smith across 1 procedure code in 2024, all of them office visits, for 46 Medicare patients. Medicare paid $440 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 46 Medicare patients who saw Dr. Smith in 2024. The largest group is 65 to 74, with 21 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Smith's median patient age at 69, with 34% women.

In 2024, Dr. Smith wrote 162 Medicare Part D claims for 83 patients. 80% of them were for generic drugs. CMS names the drug for 126 of them, across 5 drugs with 11 or more claims each, at $14,701 in total drug cost. In 2023, CMS named 346 claims across 9 drugs.

Dr. Smith accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Smith, published from 2012 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Urinary Bladder Neoplasms and Chemotherapy, Adjuvant. Dr. Smith has published most often in Int J Clin Pract. Dr. Smith's most frequent co-authors are Viktor Xavier Flores, MD, Dennis Robins, MD and Matthew R. Smith, MD, PhD.

CMS Open Payments shows 6 general payments to Dr. Smith from 6 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Progenics Pharmaceuticals, Inc. paid the most, $124.

Dr. Smith graduated from Boston University School Of Medicine in 2016.

Dr. Smith is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and MVP Health Care. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.